Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

Background: The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Pharmacother
Asıl Yazarlar: Le, Quang A., Hay, Joel W., Becker, Russell, Wang, Yamei
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Research Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311620/
https://ncbi.nlm.nih.gov/pubmed/30160186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018798034
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller